Company Overview
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Why Investors Should Care
Net profit has compounded at 43.0% per year over the last five years.
Carries low leverage with a debt-to-equity ratio of 0.25.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $10.40B (+4.9% YoY); net profit $980.00M.
- Trailing 12 Months Year-on-year growth — revenue +8.7%, earnings -44.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.1%, profit CAGR 43.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.06% |
| 1 Year: | 8.70% |
Compounded Profit Growth
| 5 Years: | 43.02% |
| 1 Year: | -44.60% |
Stock Price Performance
| 1 Year: | -19.68% |
| 6 Months: | -15.14% |
| 3 Months: | +4.55% |
| 1 Month: | -3.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.07 · Neutral
P/E of 52.76 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 43.0% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 52.8.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALC Alcon Inc. PHARMA | 69.12 | 52.76 | $33.41B | 0.51% | 4.77% | 2.94% | 6.06% | 43.02% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 2.47B | 2.60B | 2.61B | 2.72B | 2.71B |
| Cost of Revenue | 1.09B | 1.21B | 1.16B | 1.20B | 1.18B |
| Gross Profit | 1.38B | 1.39B | 1.46B | 1.52B | 1.52B |
| Operating Expenses | 915.00M | 1.14B | 1.13B | 1.20B | 1.23B |
| Operating Income | 468.00M | 247.00M | 332.00M | 313.00M | 292.00M |
| EBITDA | 773.00M | 612.00M | 521.00M | 793.00M | 614.00M |
| Interest Expense | 49.00M | 51.00M | 51.00M | 53.00M | 52.00M |
| Pretax Income | 414.00M | 199.00M | 283.00M | 264.00M | 240.00M |
| Tax Provision | 64.00M | 23.00M | 46.00M | 47.00M | 51.00M |
| Net Income | 350.00M | 176.00M | 237.00M | 217.00M | 189.00M |
| Diluted EPS | 0.70 | 0.35 | 0.48 | 0.44 | 0.39 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 8.72B | 9.46B | 9.91B | 10.40B |
| Cost of Revenue | 3.97B | 4.21B | 4.40B | 4.66B |
| Gross Profit | 4.75B | 5.25B | 5.51B | 5.75B |
| Operating Expenses | 4.08B | 4.21B | 4.10B | 4.38B |
| Operating Income | 672.00M | 1.04B | 1.41B | 1.36B |
| EBITDA | 1.72B | 2.24B | 2.68B | 2.70B |
| Interest Expense | 134.00M | 189.00M | 192.00M | 204.00M |
| Pretax Income | 463.00M | 832.00M | 1.26B | 1.16B |
| Tax Provision | 128.00M | -142.00M | 238.00M | 180.00M |
| Net Income | 335.00M | 974.00M | 1.02B | 980.00M |
| Diluted EPS | 0.68 | 1.96 | 2.05 | 1.98 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 29.16B | 29.61B | 30.35B | 31.55B |
| Current Assets | - | 5.19B | 5.65B | 6.31B | 6.45B |
| Cash & Equivalents | 1.57B | 980.00M | 1.09B | 1.68B | - |
| Inventory | - | 2.11B | 2.32B | 2.27B | 2.39B |
| Receivables | 1.59B | 1.77B | 1.89B | 1.85B | - |
| Total Liabilities | - | 9.49B | 8.99B | 30.35B | 31.55B |
| Current Liabilities | - | 2.74B | 2.40B | 2.28B | 3.05B |
| Long Term Debt | 3.97B | 4.54B | 4.68B | 4.54B | - |
| Total Debt | - | 5.07B | 5.13B | 497.00M | 509.00M |
| Total Equity | - | 19.68B | 20.62B | 21.53B | 22.01B |
| Shares Outstanding | - | 497.99M | 499.64M | 499.70M | 499.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 1.22B | 1.39B | 2.08B | 2.27B |
| Investing Cash Flow | - | -1.86B | -1.09B | -1.17B | -1.34B |
| Financing Cash Flow | - | -8.00M | -211.00M | -322.00M | -1.12B |
| Capital Expenditure | - | -745.00M | -851.00M | -670.00M | -663.00M |
| Free Cash Flow | - | 472.00M | 537.00M | 1.41B | 1.61B |
| Net Change in Cash | - | -656.00M | 83.00M | 588.00M | -192.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 54.5% | 55.5% | 55.6% | 55.2% |
| Operating Margin % | 7.7% | 11.0% | 14.3% | 13.1% |
| Net Margin % | 3.8% | 10.3% | 10.3% | 9.4% |
| ROE % | 1.7% | 4.7% | 4.7% | 4.5% |
| ROCE % | 2.5% | 3.8% | 5.0% | 4.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 2.95% | 14.75M | $959.31M |
| 2 | Bank Of New York Mellon Corporation | 2.61% | 13.06M | $849.29M |
| 3 | NORGES BANK | 2.20% | 10.98M | $713.92M |
| 4 | Invesco Ltd. | 2.08% | 10.38M | $675.14M |
| 5 | Aristotle Capital Management, LLC | 2.00% | 9.98M | $649.04M |
| 6 | AKO Capital LLP | 1.94% | 9.68M | $629.78M |
| 7 | Zurcher Kantonalbank (Zurich Cantonalbank) | 1.58% | 7.92M | $514.84M |
| 8 | FMR, LLC | 1.53% | 7.66M | $498.40M |
| 9 | UBS Group AG | 1.43% | 7.16M | $465.45M |
| 10 | Amundi | 1.33% | 6.64M | $431.71M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALC
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon's acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.
Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
GENEVA, September 03, 2026--Alcon Launches UNITY® M, a Premium Ophthalmic Microscope Delivering Precise Control
Platauro Metals Corp. - Star Project, Utah
Vancouver, British Columbia--(Newsfile Corp. - September 2, 2026) - Platauro Metals Corp. (TSXV: PURO) (OTCQB: MEXGF) ("Platauro" or the "Company") announces that its wholly-owned subsidiary, Alcon Silver Corp. ("Alcon"), is party to an opt…
Alcon (SWX:ALC), What Is Behind The Fresh Attention?
Alcon stock reacts to US Medicaid drug pricing agreement New US Medicaid drug pricing agreements involving Alcon (SWX:ALC) and eight other healthcare companies have put the stock in focus for investors assessing potential implications for i…
Mid-cap biotechs join Trump’s latest round of drug pricing deals
Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
Trump's Pharma Pricing Deal Expands as Healthcare Stocks Keep Climbing
Trump expanded his drug pricing deal to 26 pharma firms as UBS says healthcare stocks still have room to climb.
ALC — Frequently Asked Questions
What is the current share price of Alcon Inc. (ALC)?
As of 2026-09-19 21:16 PDT, Alcon Inc. (ALC) trades at $69.12 on NYSE. Its 52-week range is $62.02 to $89.68.
What is the market capitalisation of ALC?
Alcon Inc. (ALC) has a market capitalisation of $33.41B on NYSE.
What is the P/E ratio of ALC?
ALC trades at a trailing price-to-earnings (P/E) ratio of 52.76. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.53.
Does ALC pay a dividend?
Alcon Inc. (ALC) currently offers a dividend yield of 0.51%.
What is the return on equity (ROE) of ALC?
ALC has a return on equity (ROE) of 2.94%. Its return on capital employed (ROCE) is 4.77%.
Is ALC a good stock to buy?
This page provides a data-driven analysis of Alcon Inc. (ALC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.